TScan Therapeutics (TCRX) Research & Development (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Research & Development data on file, last reported at $21.9 million in Q1 2026.

• On a quarterly basis, Research & Development fell 26.47% year-over-year to $21.9 million in Q1 2026; TTM through Mar 2026 was $106.3 million, a 5.36% decrease from a year earlier, with the FY2025 full-year figure at $114.2 million, up 6.33% from the prior year.
• Research & Development for Q1 2026 stood at $21.9 million, up from $20.0 million in the prior quarter.
• Over the last five years, Research & Development for TCRX reached as high as $32.6 million in Q2 2025 and fell as low as $14.5 million in Q2 2022.
• Historically, Research & Development has averaged $23.0 million across 5 years, with a median of $22.4 million in 2023.
• Across the five-year window, Research & Development jumped 100.16% in 2022 and tumbled 31.73% in 2025, its largest moves.
• Year by year, Research & Development stood at $15.6 million in 2022, then soared by 43.59% to $22.4 million in 2023, then jumped by 31.01% to $29.4 million in 2024, then tumbled by 31.73% to $20.0 million in 2025, then advanced by 9.31% to $21.9 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $21.9 million in Q1 2026, $20.0 million in Q4 2025, and $31.7 million in Q3 2025.